Solicitation
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
HT9402-25-Q-9401
Defense Health Agency (Dha), Defense Health Agency. Pharmaceutical Preparation Manufacturing.
Response deadline
September 22, 2025 at 1:00 PM EDT
Closed 360 days ago. Posted July 29, 2025. Scheduled to archive January 24, 2026.
Description
As published on SAM.gov.
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.
The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).
Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision.
This process is described in the attached RFQ. a. Class Insulins, Subclass Rapid Acting Agents U-100 Admelog Apidra Fiasp Humalog Insulin Aspart Insulin Lispro Lyumjev Novolog Merilog b. Class Insulins, Subclass Rapid Acting Agents U-200 Lyumjev Kwikpen U-200 Humalog Kwikpen U-200 c. Class Metabolic Dysfunction Agents, Subclass Injectable Diabetic Agents Bydureon Bcise Byetta Exenatide Mounjaro Ozempic Semaglutide Tirzepatide Trulicity d. Class Metabolic Dysfunction Agents, Subclass Injectable Weight Loss Agents Saxenda Wegovy Zepbound The RFQ, including UF BPA and UF ADP appendices are attached here in.
The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9401. Pre-quotation teleconference is on July 30, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
July 29, 2025
Solicitation
Due September 22, 2025 at 1:00 PM EDT. SAM.gov, notice dcb104a0eae54362b2b5795e1e989ad7
Points of contact
- Stephanie Erpeldingstephanie.j.erpelding.civ@health.mil
- Julia Trangjulia.n.trang.civ@health.mil
Also open from this buyer
- Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount ProgramSolicitationNAICS 325412HT9402-26-Q-9403Closes in 7 daysSep 24
- Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount ProgramSolicitationNAICS 325412TexasHT9402-26-Q-9401Closes in 14 daysOct 1